View Older Stories View More Recent Stories

May 8, 2024 07:00AM PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 8, 2024 07:00AM PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 1, 2024 07:00AM PolyPid to Participate in Citizens JMP Life Sciences Conference
Apr 30, 2024 07:00AM PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
Apr 24, 2024 07:00AM PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
Feb 28, 2024 07:00AM PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
Feb 14, 2024 07:00AM PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 12, 2024 07:00AM PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
Feb 12, 2024 07:00AM PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
Jan 31, 2024 07:00AM PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
Jan 4, 2024 04:33PM PolyPid Ltd. (PYPD) Announces $16.2M Private Placement at $4.81/sh
Jan 4, 2024 04:32PM PolyPid Announces Private Placement for $16 Million in Gross Proceeds
Nov 8, 2023 07:00AM PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Nov 7, 2023 07:02AM PolyPid Ltd. (PYPD) Appoints Nurit Tweezer-Zaks to its Board
Nov 7, 2023 07:00AM PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
Nov 1, 2023 07:00AM PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
Oct 11, 2023 07:01AM PolyPid Ltd. (PYPD) Regains Nasdaq Compliance
Oct 11, 2023 07:00AM PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Oct 9, 2023 07:00AM PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
Oct 4, 2023 07:02AM PolyPid Ltd. (PYPD) Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX and PLEX Technology Platform
Oct 4, 2023 07:00AM PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
Sep 22, 2023 07:00AM PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
Sep 21, 2023 07:34AM PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
Sep 20, 2023 09:15AM PolyPid Ltd. (PYPD) Announces 1:30 Reverse Share Split
Sep 20, 2023 09:15AM PolyPid Announces Reverse Share Split
Sep 19, 2023 07:00AM PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
Aug 9, 2023 07:00AM PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Jul 26, 2023 07:00AM PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
Jun 29, 2023 08:00AM PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
Jun 22, 2023 07:00AM PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
Jun 5, 2023 04:02PM PolyPid Ltd. (PYPD) Granted 180-Day Extension to Regain Nasdaq Compliance
Jun 5, 2023 04:02PM PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
May 22, 2023 09:01AM PolyPid Ltd. (PYPD) Announces FDA Agreement of Design of SHIELD II Phase 3 Trial
May 22, 2023 09:00AM PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
May 10, 2023 07:00AM PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
Apr 26, 2023 07:00AM PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
Apr 24, 2023 07:00AM PolyPid to Participate in Upcoming Investor Conferences
Apr 14, 2023 04:01PM PolyPid Ltd. (PYPD) Receives Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
Apr 14, 2023 04:01PM PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
Mar 31, 2023 12:00PM PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
Mar 29, 2023 08:00AM PolyPid Ltd. (PYPD) Prices 6.2M Share Offerings at $0.42/sh, Concurrent $4.4M Placement of Pre-Funded Warrants
Mar 29, 2023 07:59AM PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
Mar 28, 2023 04:05PM PolyPid Ltd. (PYPD) Announces Proposed Share Offering
Mar 28, 2023 04:05PM PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
Mar 7, 2023 08:00AM PolyPid to Present at the Barclays Global Healthcare Conference
Feb 8, 2023 07:00AM PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Jan 31, 2023 07:00AM PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
Jan 24, 2023 07:05AM PolyPid (PYPD) Provides Positive Regulatory Update for D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Jan 24, 2023 07:00AM PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Jan 3, 2023 07:02AM PolyPid Ltd. (PYPD) announces publication of a post-hoc analysis from the previously-completed Phase 2 study of D-PLEX100
View More Recent Stories View Older Stories